GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges

E-ISSN： 1873-5592|17|11|1292-1300

ISSN： 1389-4501

Source： Current Drug Targets, Vol.17, Iss.11, 2016-07, pp. : 1292-1300

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The therapeutic potential of GPR119 agonists for type 2 diabetes

By Ohishi Takahide Yoshida Shigeru

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 3, 2012-03 ,pp. : 321-328

Informa Healthcare

Access to resources Recommend Favorite

Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors

By Holst Jens Juul

Expert Opinion on Emerging Drugs, Vol. 9, Iss. 1, 2004-05 ,pp. : 155-166

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus

Current Clinical Pharmacology, Vol. 12, Iss. 4, 2018-04 ,pp. : 202-209

Bentham Science Publishers

Access to resources Recommend Favorite

Orlistat: In the Prevention and Treatment of Type 2 Diabetes Mellitus

By Keating G.M. Jarvis B.

Drugs, Vol. 61, Iss. 14, 2001-01 ,pp. : 2107-2119

Adis International

Access to resources Recommend Favorite

Meglitinide Analogues in the Treatment of Type 2 Diabetes Mellitus

By Landgraf R.

Drugs & Aging, Vol. 17, Iss. 5, 2000-11 ,pp. : 411-425

Adis International

Access to resources Recommend Favorite